323 related articles for article (PubMed ID: 38205881)
1. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer.
Rutherford KA; McManus KJ
Mol Cancer Ther; 2024 Apr; 23(4):454-463. PubMed ID: 38205881
[TBL] [Abstract][Full Text] [Related]
2. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C; Zhang Y; Chen W; Wu Y; Xing D
Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
[TBL] [Abstract][Full Text] [Related]
3. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
Zhang R; Xie S; Ran J; Li T
J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
[TBL] [Abstract][Full Text] [Related]
4. N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances.
Banerjee S; Sharma S; Thakur A; Sachdeva R; Sharma R; Nepali K; Liou JP
Curr Drug Targets; 2023; 24(15):1184-1208. PubMed ID: 37946353
[TBL] [Abstract][Full Text] [Related]
5. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
Wang C; Zhang Y; Xing D; Zhang R
Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
[TBL] [Abstract][Full Text] [Related]
6. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
7. PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives.
Vicente ATS; Salvador JAR
MedComm (2020); 2024 Jun; 5(6):e575. PubMed ID: 38845697
[TBL] [Abstract][Full Text] [Related]
8. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
[TBL] [Abstract][Full Text] [Related]
9. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
[TBL] [Abstract][Full Text] [Related]
10. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.
Moon Y; Jeon SI; Shim MK; Kim K
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839734
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
15. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
17. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.
Vorderbruggen M; Velázquez-Martínez CA; Natarajan A; Karpf AR
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791105
[TBL] [Abstract][Full Text] [Related]
18. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
[TBL] [Abstract][Full Text] [Related]
19. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC).
Dogheim GM; Amralla MT
Drug Dev Res; 2023 Jun; 84(4):629-653. PubMed ID: 37020351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]